Read our COVID-19 research and news.

Webinar Technology

When proteins get personal: A new concept for highly sensitive, multiplexed plasma profiling

This webinar is brought to you by the Science/AAAS Custom Publishing Office

When proteins get personal: A new concept for highly sensitive, multiplexed plasma profiling

02 September 2020

12:00 p.m. ET

Register to watch recording


New high-throughput 'omics tools capable of performing genomic, proteomic, and metabolomic analysis using clinical samples have opened up unique possibilities to study both health and disease with high analytical precision and clinical accuracy. Studying the proteins secreted into the bloodstream can provide insights into many important biological processes as well as potential targets for diagnostics and therapies. Multiplex technologies enabling the analysis of thousands of protein targets from minute amounts of plasma or serum have opened up a new field in precision medicine, in which the levels of thousands of blood proteins can be efficiently monitored. This allows for variations in protein concentrations within an individual to be tracked over time—including during drug treatment—and for comparisons to be drawn between healthy and diseased individuals. In this webinar, our expert speakers will describe two multiplex platforms used to rapidly analyze blood proteins using quantitative PCR and next-generation sequencing, which have been instrumental in a 2-year longitudinal wellness study involving repeated sampling of individuals. Analysis included classical clinical chemistry, advanced medical imaging, and extensive 'omics profiling focusing on the plasma proteome and completed by whole-genome sequencing, as well as an exploration of the plasma metabolome, the transcriptome, blood-cell composition (immune cytome), autoantibody reactivity profiles, and gut microbiota composition.

During the webinar, viewers will learn about:

  • Assays that can be used to analyze more than a thousand protein targets in blood from very small blood samples
  • A longitudinal wellness study showing that individuals have unique, stable plasma protein profiles that correlate strongly with clinical chemistry parameters
  • Blood proteins that are impacted by drug treatment, as exemplified by the analysis of patients treated for type 2 diabetes
  • Results that support an individual-based definition of health and show the advantages of longitudinal 'omics profiling for precision medicine.

Audience questions will be answered during the live broadcast.

This webinar will last for approximately 60 minutes.

Speaker bios

Mathias Uhlén, Ph.D.

KTH Royal Institute of Technology
Stockholm, Sweden

Dr. Uhlén received his Ph.D. in chemistry at the Royal Institute of Technology (KTH) in Stockholm, Sweden. After postdoctoral training at the European Molecular Biology Laboratory in Heidelberg, Germany, he became professor of microbiology at KTH in 1988. Dr. Uhlén founded the Science for Life Laboratory in Stockholm, Sweden, where he served as director from 2010 to 2015, and has authored more than 750 publications in bioscience with a focus on the development and use of affinity reagents in biotechnology and biomedicine. He has founded 10 companies and has more than 70 patents and patent applications to his name. He is a member of the Royal Swedish Academy of Engineering Sciences, the Royal Swedish Academy of Sciences, the European Molecular Biology Organization, and the National Academy of Engineering, and is president of the European Federation of Biotechnology. He was the first to describe the use of affinity tags for purification of proteins and the use of biotin-streptavidin for DNA handling, methods now widely used in bioscience. He is leading the international effort to create the Human Protein Atlas with the aim of systematically mapping the entire human proteome. Dr. Uhlén has received numerous awards, including the AkzoNobel Science Award, the Seraphim Medal from His Majesty the King of Sweden, the HUPO Distinguished Achievement in Proteomic Sciences Award, and the ABRF Award for Outstanding Contributions to Biomolecular Technologies.

Ida Grundberg, Ph.D.

Olink Proteomics
Uppsala, Sweden

Dr. Grundberg received her Ph.D. at Uppsala University in Sweden from the prestigious research group that founded Olink and developed its key technology. She continued as a senior scientist at Olink, responsible for working toward commercialization of the patented technology developed during her doctorate. Following the market release of Olink’s multiplex product, Dr. Grundberg joined the commercial side of the business and, in 2015, was promoted to lead the U.S. market entry program on the strength of her scientific understanding of Olink’s products and her commercial experience. She recently took on the role of chief scientific officer at the company, leading the global Scientific Affairs team.

Sean Sanders, Ph.D.

Washington, DC

Dr. Sanders did his undergraduate training at the University of Cape Town, South Africa, and his Ph.D. at the University of Cambridge, UK, supported by the Wellcome Trust. Following postdoctoral training at the National Institutes of Health and Georgetown University, Dr. Sanders joined TranXenoGen, a startup biotechnology company in Massachusetts working on avian transgenics. Pursuing his parallel passion for writing and editing, Dr. Sanders joined BioTechniques as an editor, before joining Science/AAAS in 2006. Currently, Dr. Sanders is the Director and Senior Editor for Custom Publishing for the journal Science and Program Director for Outreach.

Sponsored by

Get webinar alerts

For more information on upcoming webinars, recorded sessions and more, sign up for webinar alerts.

Sign up here